GlassScriptPhysician profile
Emily Renee Watson
NPI 1811323710
$7,070.50
in general payments reported to CMS, 2019-2025
24 companies · $1,454 in 2025
The $1,454 reported for 2025 was more than what 94% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $713 · 2022: $1,622 · 2023: $2,023 · 2024: $1,258 · 2025: $1,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,443 · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,443.47 |
| Education | $291.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,248.19 | 2021-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $1,097.67 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $955.66 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Lilly USA, LLC | $601.38 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $548.66 | 2022-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $408.94 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $386.19 | 2021-2025 | Dupixent |
| Leo Pharma INC. | $272.42 | 2021-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $220.42 | 2023-2025 | Cabtreo, Jublia, Siliq |
| Genzyme Corporation | $196.25 | 2021-2025 | |
| Ucb, INC. | $182.81 | 2021-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $156.65 | 2023-2025 | Zoryve |
| Pfizer INC. | $152.06 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $149.40 | 2022-2023 | Tremfya |
| Dermavant Sciences, INC. | $96.44 | 2023-2024 | Vtama |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $92.00 | 2022 | |
| Almirall LLC | $75.62 | 2021-2025 | Klisyri |
| Biofrontera INC. | $60.62 | 2022-2025 | |
| Amgen INC. | $58.09 | 2022-2024 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.20 | 2022 | |
| Allergan, INC. | $22.45 | 2022 | |
| Verrica Pharmaceuticals INC. | $21.56 | 2024 | Ycanth |
| Novartis Pharmaceuticals Corporation | $17.84 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $16.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Renee Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.